T1	Concept 87 97	SARS-CoV-2
T2	Concept 102 112	Human SARS
T3	Concept 135 142	Bat CoV
T4	Concept 42 58	disorder segment
T5	Concept 37 41	long
R1	has-property Arg1:T4 Arg2:T5	
T6	Concept 0 4	Nsp8
T7	Concept 5 13	proteins
R2	is-a Arg1:T6 Arg2:T7	
T8	Action 17 26	predicted
R3	subject Arg1:T8 Arg2:T6	
R4	target Arg1:T8 Arg2:T4	
T9	Concept 64 78	44-84 residues
R5	in-context Arg1:T4 Arg2:T9	
R6	in-context Arg1:T9 Arg2:T1	
R7	in-context Arg1:T9 Arg2:T2	
T10	Concept 117 131	48-84 residues
R8	in-context Arg1:T4 Arg2:T10	
R9	in-context Arg1:T10 Arg2:T3	
T12	Concept 205 215	SARS-COV-2
T13	Concept 216 226	Human SARS
T14	Concept 232 239	Bat CoV
T15	Concept 253 262	mean PPID
T16	Concept 656 676	SARS-COV-2 infection
T17	Concept 716 728	liver injury
A1	Uncertain T16
R10	causes Arg1:T16 Arg2:T17	
T18	Concept 769 780	respiratory
T19	Concept 784 797	blood samples
T20	Concept 810 816	RT-PCR
T21	Concept 922 932	SARS-CoV-2
T22	Concept 860 873	blood samples
T23	Concept 179 187	disorder
T24	Concept 169 178	intrinsic
R11	has-property Arg1:T23 Arg2:T24	
T25	Concept 551 561	SARS-CoV-2
T26	Concept 742 752	SARS-CoV-2
T27	Concept 753 765	nucleic acid
R16	has-part Arg1:T26 Arg2:T27	
R17	in-place Arg1:T27 Arg2:T18	
R18	in-place Arg1:T27 Arg2:T19	
T28	Concept 729 737	Positive
R19	has-property Arg1:T27 Arg2:T28	
T29	Action 798 806	detected
R20	subject Arg1:T29 Arg2:T27	
R21	target Arg1:T29 Arg2:T20	
T30	Concept 845 856	respiratory
T31	Concept 886 894	homology
A2	Emphasized T31
T32	Concept 818 832	Virus sequence
T33	Action 874 880	shares
R22	subject Arg1:T33 Arg2:T32	
R23	target Arg1:T33 Arg2:T31	
R24	in-context Arg1:T31 Arg2:T21	
R25	in-place Arg1:T32 Arg2:T30	
R26	in-place Arg1:T32 Arg2:T22	
T35	Concept 525 542	antiviral effects
A3	Uncertain T35
T34	Concept 392 412	therapeutic shortcut
R27	in-context Arg1:T35 Arg2:T25	
T36	Concept 608 620	clinical use
T37	Concept 633 648	clinical trials
T38	Action 595 603	approved
R28	target Arg1:T38 Arg2:T36	
R29	target Arg1:T38 Arg2:T37	
T39	Concept 574 579	drugs
R30	subject Arg1:T38 Arg2:T39	
R31	has-property Arg1:T39 Arg2:T35	
T43	Concept 191 192;193 201	M proteins
T44	Concept 191 192;193 201	M proteins
R13	in-place Arg1:T44 Arg2:T12	
R15	in-place Arg1:T43 Arg2:T14	
R34	in-place Arg1:T23 Arg2:T44	
R35	in-context Arg1:T23 Arg2:T43	
T11	Concept 191 192;193 201	M proteins
R12	in-place Arg1:T23 Arg2:T11	
R14	in-place Arg1:T11 Arg2:T13	
T45	Action 325 336	development
T46	Concept 346 350	drug
T47	Concept 342 345	new
R36	has-property Arg1:T46 Arg2:T47	
R37	target Arg1:T45 Arg2:T46	
T48	Concept 367 372	years
A4	Uncertain T48
R38	in-time Arg1:T45 Arg2:T48	
T49	Concept 266 271	2.70%
T50	Concept 273 278	1.36%
T51	Concept 284 289	1.36%
R39	in-context Arg1:T23 Arg2:T15	
T52	Concept 387 391	best
T40	Concept 429 456	drug repositioning strategy
T41	Concept 448 456	strategy
R32	is-a Arg1:T40 Arg2:T41	
A5	Emphasized T52
A6	Uncertain T52
T42	Action 464 471	finding
T53	Concept 476 479	new
T54	Concept 480 484	uses
T55	Concept 492 497	drugs
T56	Concept 488 491	old
R41	target Arg1:T42 Arg2:T54	
R42	has-property Arg1:T54 Arg2:T53	
R43	in-context Arg1:T54 Arg2:T55	
R44	has-property Arg1:T55 Arg2:T56	
*	same-as T40 T42
T57	Action 419 424	apply
R33	is-a Arg1:T57 Arg2:T34	
R40	has-property Arg1:T57 Arg2:T52	
R45	target Arg1:T57 Arg2:T40	
T58	Action 502 510	identify
R46	in-context Arg1:T57 Arg2:T58	
R47	causes Arg1:T45 Arg2:T57	
R48	target Arg1:T58 Arg2:T35	
